CompView Medical announced the release of the NuCART, a turn-key, all-in-one mobile boom system with integrated visualization.

August 21, 2015 — Loyola University Medical Center is the first and only hospital in Illinois to offer a new, noninvasive technology to test for coronary artery disease.

The technology employs noninvasive CT scans to calculate how much blood is flowing through diseased coronary arteries that have narrowed due to a buildup of plaque. The patient does not need to undergo an invasive angiogram that involves threading a catheter to the heart.

August 21, 2015 — A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy.

Non-invasive stereotactic body radiation therapy (SBRT) is effective and well-tolerated by patients with inoperable early-stage or node-negative non-small cell lung cancer (NSCLC) tumors larger than 5 cm, according to a study published in the International Journal of Radiation Oncology Biology Physics.

A national risk model that gauges a woman’s chance of developing breast cancer has been refined to give a more accurate assessment. The revised figures, based on data from more than 1 million patients, reveal a 300 percent increase in a subset of women whose five-year risk is estimated at 3 percent or higher.

The biggest trends at the recent Association for Medical Imaging Management (AHRA) annual meeting included concerns over ICD-10 conversion, X-ray radiation dose reduction, tracking technologies, new breast tomosynthesis imaging, interest in creating CT lung cancer screening programs and advances in digital radiography systems. 

AHRA President Dave Fox gave a brief overview of the conference and some of the hot topics in a video interview with ITN

ScanMed LLC CEO Randall Jones, Ph.D., MBA, introduced the prostate/pelvic magnetic resonance imaging (MRI) coil dedicated to prostate cancer detection on Omaha's CBS Action News 3 segment "The Morning Blend."

Guided Therapeutics Inc. announced that it has presented the U.S. Food and Drug Administration (FDA) with a plan for advancing the pre-market approval (PMA) application for the LuViva Advanced Cervical Scan. In its “pre-submission” letter, the company also requested a meeting with the agency to finalize the plan.

The ITM Group announced that its subsidiary ITG GmbH has successfully in-licensed DOTA-Zoledronate, a next-generation theranostic agent for bone targeted radionuclide therapy and diagnostics in patients suffering from bone metastases. DOTA-Zoledronate specifically targets cancerous bone lesions and, when radiolabeled with therapeutic or diagnostic radioisotopes, has shown high potential for positron emission tomography (PET) imaging and endoradiotherapy.

Subscribe Now